[go: up one dir, main page]

WO2004022039A3 - Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system - Google Patents

Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system Download PDF

Info

Publication number
WO2004022039A3
WO2004022039A3 PCT/CA2003/001291 CA0301291W WO2004022039A3 WO 2004022039 A3 WO2004022039 A3 WO 2004022039A3 CA 0301291 W CA0301291 W CA 0301291W WO 2004022039 A3 WO2004022039 A3 WO 2004022039A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
neurodegenerative diseases
injuries
guanosine
inosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001291
Other languages
French (fr)
Other versions
WO2004022039A2 (en
Inventor
Francesco Caciagli
Renata Ciccarelli
Iorio Patrizia Di
Sonya Kleywegt
Eva Susanne Werstiuk
Michel P Rathbone
Eva Vertes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROLOGICAL TECHNOLOGIES Inc
Original Assignee
NEUROLOGICAL TECHNOLOGIES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROLOGICAL TECHNOLOGIES Inc filed Critical NEUROLOGICAL TECHNOLOGIES Inc
Priority to AU2003264195A priority Critical patent/AU2003264195A1/en
Priority to CA002497437A priority patent/CA2497437A1/en
Publication of WO2004022039A2 publication Critical patent/WO2004022039A2/en
Anticipated expiration legal-status Critical
Publication of WO2004022039A3 publication Critical patent/WO2004022039A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for preventing apoptosis are described. The method involves administering an effective amount of a purine nucleoside to a cell or an animal in need thereof. The methods are useful in treating diseases of the nervous system including neurodegenerative diseases, stroke or spinal cord injuries.
PCT/CA2003/001291 2002-09-03 2003-09-03 Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system Ceased WO2004022039A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003264195A AU2003264195A1 (en) 2002-09-03 2003-09-03 Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
CA002497437A CA2497437A1 (en) 2002-09-03 2003-09-03 Purine nucleosides as anti-apoptotic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40731002P 2002-09-03 2002-09-03
US60/407,310 2002-09-03

Publications (2)

Publication Number Publication Date
WO2004022039A2 WO2004022039A2 (en) 2004-03-18
WO2004022039A3 true WO2004022039A3 (en) 2008-01-03

Family

ID=31978454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001291 Ceased WO2004022039A2 (en) 2002-09-03 2003-09-03 Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system

Country Status (3)

Country Link
AU (1) AU2003264195A1 (en)
CA (1) CA2497437A1 (en)
WO (1) WO2004022039A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016359A1 (en) * 2003-08-19 2005-02-24 Neurological Technologies Inc. Method of promoting remyelination
RU2311180C2 (en) * 2005-04-28 2007-11-27 Галина Викторовна Сукоян Agent for preventing progression of apoptotic and arresting necrotic alterations in body tissue
AR058834A1 (en) * 2006-11-06 2008-02-27 Univ Nac Quilmes A COMPOSITE WITH INHIBITORY ACTIVITY OF A RHO-GTPASA CELL PROTEIN, A PROCEDURE FOR OBTAINING IT, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND A METHOD FOR THE TREATMENT OF AN INDICATION MEDIATED BY A RHO-GTPASA CELL PROTEIN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000132A1 (en) * 1992-06-24 1994-01-06 Pierre Fabre Medicament Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction
WO1999011274A1 (en) * 1997-09-02 1999-03-11 Children's Medical Center Corporation Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000132A1 (en) * 1992-06-24 1994-01-06 Pierre Fabre Medicament Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction
WO1999011274A1 (en) * 1997-09-02 1999-03-11 Children's Medical Center Corporation Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUURLINK B H J ET AL: "AIT-082 (A HYPOXANTHINE DERIVATIVE), GUANOSINE AND METABOLITES STIMULATE NEURITE FORMATION IN HIPPOCAMBIAL NEURONS", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 43, no. 1, January 1998 (1998-01-01), pages 55, XP002166458, ISSN: 0272-4391 *
LITSKY M L ET AL: "INOSINE AND GUANOSINE PRESERVE NEURONAL AND GLIAL CELL VIABILITY INMOUSE SPINAL CORD CULTURES DURING CHEMICAL HYPOXIA", BRAIN RESEARCH, AMSTERDAM, NL, vol. 821, no. 2, 1999, pages 426 - 432, XP000995702, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
CA2497437A1 (en) 2004-03-18
AU2003264195A8 (en) 2008-02-28
AU2003264195A1 (en) 2004-03-29
WO2004022039A2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
MXPA05002791A (en) Non-sequence complementary antiviral oligonucleotides.
WO2004060146A3 (en) Method of treatment for central nervous system injury
DK1578439T3 (en) Low-dose approach to treat disorders in which TNF-alpha activity is harmful
AU2003249356A1 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
IL225192A (en) Combination of dextromethorphan and quinidine for use in the treatment of mental illness, neuropathic pain or brain injury
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
WO2002043652A3 (en) Anti-proliferative drugs
WO2005000215A3 (en) Methods for treating pain
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
BR0316157A (en) 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo [2,3-d] pyrimidine derivatives
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
BRPI0411120A (en) method for treating an anxiety disorder, composition, agent for treating an anxiety disorder, and uses of a compound and xanthine derivative
TWI347846B (en)
WO2006041800A3 (en) 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel
WO2004022039A3 (en) Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1569903A4 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2003227593A1 (en) New analogs of nitrobenzylthioinosine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2497437

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP